Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAS825 open-label phase II trial in pediatric and adult patients with Still's disease
2024-520208-25-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of MAS825 in adult-onset Still's disease (AOSD), sponsored by Novartis. Primary endpoint: Clinical response by composite endpoint. Planned start Jan 2026; status: authorised.
02
Drugs
MAS825
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on 2024-520208-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520208-25-00.